Report Sections

See All Reports

  • HP:0002098: Respiratory distress
  • Pneumonia (382) Neoplasm (47) Respiratory tract infection (46) Diabetes mellitus (39) Abnormality of the cardiovascular system (39) Depressivity (35) Abnormal lung morphology (33) Hypoxemia (30) Acute kidney injury (29) Hypertension (25) Thromboembolism (23) Myocardial infarction (22) Anosmia (21) Mental deterioration (21) Arthritis (20) Type II diabetes mellitus (20) Chronic pulmonary obstruction (19) Leukemia (18) Pulmonary fibrosis (18) Pulmonary obstruction (18) Abnormality of the kidney (17) Stroke (17) Congestive heart failure (16) Abnormality of coagulation (16) Pulmonary embolism (16) Neoplasm of the lung (16) Rheumatoid arthritis (15) Asthma (15) Interstitial pneumonitis (15) Crohn's disease (15) Autistic behavior (14) Chronic pain (14) Type I diabetes mellitus (13) Deep venous thrombosis (12) Ulcerative colitis (12) Autism (11) Obesity (11) Respiratory distress (11) Colitis (11) Carcinoma (11) Alzheimer disease (10) Lymphoma (10) Chronic kidney disease (10) Myocarditis (10) Low levels of vitamin D (10) Sepsis (10) Renal insufficiency (9) Dementia (9) Abnormality of the liver (9) Coronary artery atherosclerosis (9) Weight loss (9) Inflammation of the large intestine (9) Pulmonary insufficiency (9) Behavioral abnormality (8) Psychosis (8) Infertility (8) Abnormality of the gastrointestinal tract (8) Migraine (7) Breast carcinoma (7) Psoriasiform dermatitis (7) Peripheral arterial stenosis (7) Fatigue (7) Schizophrenia (7) Encephalopathy (6) Lymphopenia (6) Dysphagia (6) Bronchiectasis (6) Immunodeficiency (6) Systemic lupus erythematosus (6) Osteoarthritis (6) Obstructive sleep apnea (6) Sleep apnea (6) Prostate cancer (6) Non-small cell lung carcinoma (6) Neoplasm of the large intestine (6) Seizure (5) Premature birth (5) Difficulty walking (5) Gastroparesis (5) Neoplasm of the pancreas (5) Autoimmunity (5) Knee osteoarthritis (5) Disseminated intravascular coagulation (5) Lymphoid leukemia (5) Inflammatory abnormality of the skin (5) Neoplasm of head and neck (5) Allergy (5) Eczema (4) Atopic dermatitis (4) Hepatic fibrosis (4) Cardiac arrest (4) Abnormality of blood and blood-forming tissues (4) Pulmonary arterial hypertension (4) Abnormal intestine morphology (4) Headache (4) Colon cancer (4) Reduced factor VIII activity (4) Malnutrition (4) Paroxysmal atrial fibrillation (4) Renal cell carcinoma (4) Abnormal anterior horn cell morphology (4) Attention deficit hyperactivity disorder (4) Amyotrophic lateral sclerosis (4) Arrhythmia (4) Endometriosis (4) Addictive behavior (4) Hypercoagulability (4) Insomnia (4) Abnormality of the eye (3) Obsessive-compulsive behavior (3) Abnormality of the endocrine system (3) Spastic diplegia (3) Polyneuropathy (3) Meningitis (3) Hepatic steatosis (3) Abnormal heart morphology (3) Cardiomyopathy (3) Tachycardia (3) Fever (3) Hypothermia (3) Apnea (3) Celiac disease (3) Myelodysplasia (3) Acute myeloid leukemia (3) Myeloproliferative disorder (3) Chronic lymphatic leukemia (3) Multiple myeloma (3) Cystoid macular edema (3) Postprandial hyperglycemia (3) Cutaneous melanoma (3) Small cell lung carcinoma (3) Pulmonary edema (3) Ovarian neoplasm (3) Neuroendocrine neoplasm (3) Bulimia (3) Hypogeusia (2) Hearing impairment (2) Visual impairment (2) Conjunctivitis (2) Cataract (2) Uveitis (2) Periodontitis (2) Agoraphobia (2) Nephrolithiasis (2) Abnormality of the thyroid gland (2) Abnormality of the skin (2) Jaundice (2) Lymphedema (2) Keratoconjunctivitis sicca (2) Spasticity (2) Hemiparesis (2) Abnormal joint morphology (2) Aortic valve stenosis (2) Angina pectoris (2) Pancreatitis (2) Thrombocytopenia (2) Autoimmune thrombocytopenia (2) Gout (2) Diarrhea (2) Gastroesophageal reflux (2) Neurodegeneration (2) Alopecia of scalp (2) Mutism (2) Transient ischemic attack (2) Hyperkinetic movements (2) Polyphagia (2) Hypotension (2) Atherosclerosis (2) Hypoventilation (2) Squamous cell carcinoma (2) Male infertility (2) Back pain (2) Low back pain (2) Muscular dystrophy (2) Stillbirth (2) Chronic bronchitis (2) Lymphoproliferative disorder (2) Intervertebral disc degeneration (2) Stomatitis (2) Stridor (2) Hemeralopia (2) Arteritis (2) Hepatitis (2) Glioblastoma multiforme (2) B-cell lymphoma (2) Myeloid leukemia (2) Bronchitis (2) Pain (2) Cervix cancer (2) Cholangitis (2) Endocarditis (2) Toxemia of pregnancy (2) Myositis (2) Mania (2) Urinary retention (1) Urinary incontinence (1) Nephritis (1) Menorrhagia (1) Xerostomia (1) Otitis media (1) Conductive hearing impairment (1) Amblyopia (1) Abnormality of the nervous system (1) Aggressive behavior (1) IgA deposition in the glomerulus (1) Oligospermia (1) Enuresis (1) Hypoparathyroidism (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Osteopenia (1) Urticaria (1) Angiokeratoma corporis diffusum (1) Cholecystitis (1) Keratoconjunctivitis (1) Intellectual disability (1) Syncope (1) Cerebral hemorrhage (1) Hepatic failure (1) Hepatocellular carcinoma (1) Intrauterine growth retardation (1) Hoarse voice (1) Dysphonia (1) Weak voice (1) Sudden cardiac death (1) Cor pulmonale (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Premature rupture of membranes (1) Iron deficiency anemia (1) Anemia (1) Dehydration (1) Constipation (1) Anorexia (1) Esophageal varix (1) Chorea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Abnormality of the spinal cord (1) Hyperkalemia (1) Memory impairment (1) Encephalitis (1) Spina bifida (1) Language impairment (1) Myelomeningocele (1) Waddling gait (1) Increased intracranial pressure (1) Biliary cirrhosis (1) Vascular dilatation (1) Recurrent E. coli infections (1) Osteomyelitis (1) Tachypnea (1) Central apnea (1) Embryonal neoplasm (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Allergic rhinitis (1) Skeletal muscle atrophy (1) Spondylolisthesis (1) Myalgia (1) Bruxism (1) Neonatal death (1) Increased body weight (1) Enterocolitis (1) Intermittent claudication (1) Thrombophlebitis (1) Supraventricular tachycardia (1) Ventricular tachycardia (1) Acute myelomonocytic leukemia (1) Dilatation of the cerebral artery (1) Coronary artery stenosis (1) Spontaneous abortion (1) Venous insufficiency (1) Monoclonal immunoglobulin M proteinemia (1) Abnormality of bone marrow cell morphology (1) Hypersensitivity pneumonitis (1) Intraalveolar phospholipid accumulation (1) Neoplasm of the genitourinary tract (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Bladder neoplasm (1) Uterine neoplasm (1) Intestinal atresia (1) Tonsillitis (1) Placental abruption (1) Sinus tachycardia (1) Bronchiolitis (1) Erythroid hypoplasia (1) Asterixis (1) Hodgkin lymphoma (1) Ciliary dyskinesia (1) Chronic myelomonocytic leukemia (1) Morphea (1) Rhinitis (1) Seasonal allergy (1) Hypercapnia (1) Restless legs (1) Non-Hodgkin lymphoma (1) Membranous nephropathy (1) Retinal vein occlusion (1) Vasovagal syncope (1) Heart block (1) Cough (1) Neonatal asphyxia (1) Dyspareunia (1) Ductal carcinoma in situ (1) Heart murmur (1) Cardiogenic shock (1) Cholangiocarcinoma (1) Vulvar neoplasm (1) Brain neoplasm (1) Femur fracture (1) Neonatal sepsis (1) Glue ear (1) Abnormality of movement (1) Sarcoma (1) Subdural hemorrhage (1) Biliary tract neoplasm (1) Nasal polyposis (1) Rectal fistula (1) Eclampsia (1) Esophagitis (1) Vaginal neoplasm (1) Cellulitis (1) Angioedema (1) Self-injurious behavior (1) Gastrointestinal stroma tumor (1) Neoplasm of the rectum (1) Chest pain (1) Atelectasis (1) Halitosis (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0002098: Respiratory distress

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (23)


    Name (Synonyms) Correlation
    drug2773 Nebulized administration of RLF-100 or Placebo Wiki 0.30
    drug431 Auscul-X Wiki 0.30
    drug2831 No intervention / Compare the difference in respiratory rate between H0 and H12 of the initiation of morphine between the control and interventional groups Wiki 0.30
    Name (Synonyms) Correlation
    drug1947 Hydrogen Oxygen Generator with Nebulizer Wiki 0.30
    drug5227 specific exercise rehabilitation treatment Wiki 0.30
    drug3581 Rapid diagnostics using Anyplex TMII RV16 Detection Wiki 0.30
    drug1576 Experimental Group Wiki 0.30
    drug3810 SELF-BREATHE Wiki 0.30
    drug1281 Delayed diagnostics Anyplex TMII RV16 Detection Wiki 0.30
    drug3223 Placebo Group Wiki 0.30
    drug332 Anti-SARS-CoV-2 immunoglobulin Wiki 0.30
    drug2276 Knowledge, Attitude, Practice, Awareness, Preference Wiki 0.30
    drug4141 Standard-of-care Wiki 0.30
    drug4109 Standard of Care Treatment Wiki 0.21
    drug1258 Data Collection Wiki 0.21
    drug3537 RLF-100 (aviptadil) Wiki 0.21
    drug3525 RECOP unit patient Wiki 0.21
    drug3218 Placebo Comparator Wiki 0.21
    drug541 Bacille Calmette-Guérin (BCG) Wiki 0.21
    drug2810 Nitric Oxide Wiki 0.15
    drug226 Ad26.COV2.S Wiki 0.13
    drug1213 Cyclosporine Wiki 0.13
    drug3195 Placebo Wiki 0.01

    Correlated MeSH Terms (21)


    Name (Synonyms) Correlation
    D004417 Dyspnea NIH 1.00
    D005335 Fever of Unknown Origin NIH 0.30
    D002637 Chest Pain NIH 0.30
    Name (Synonyms) Correlation
    D063806 Myalgia NIH 0.30
    D017093 Liver Failure NIH 0.30
    D000755 Anemia, Sickle Cell NIH 0.15
    D001987 Bronchiectasis NIH 0.12
    D055370 Lung Injury NIH 0.11
    D003550 Cystic Fibrosis NIH 0.10
    D017563 Lung Diseases, Interstitial NIH 0.08
    D012127 Respiratory Distress Syndrome, Newborn NIH 0.07
    D055371 Acute Lung Injury NIH 0.07
    D012128 Respiratory Distress Syndrome, Adult NIH 0.07
    D008171 Lung Diseases, NIH 0.05
    D004630 Emergencies NIH 0.05
    D011024 Pneumonia, Viral NIH 0.03
    D011014 Pneumonia NIH 0.03
    D007239 Infection NIH 0.03
    D045169 Severe Acute Respiratory Syndrome NIH 0.03
    D018352 Coronavirus Infections NIH 0.02
    D003141 Communicable Diseases NIH 0.02

    Correlated HPO Terms (7)


    Name (Synonyms) Correlation
    HP:0100749 Chest pain HPO 0.30
    HP:0003326 Myalgia HPO 0.30
    HP:0001399 Hepatic failure HPO 0.30
    Name (Synonyms) Correlation
    HP:0002110 Bronchiectasis HPO 0.12
    HP:0006515 Interstitial pneumonitis HPO 0.08
    HP:0002088 Abnormal lung morphology HPO 0.05
    HP:0002090 Pneumonia HPO 0.03

    Clinical Trials

    Navigate: Correlations   HPO

    There are 11 clinical trials


    1 The Impact of Respiratory Pathogen PCR Assay on Treatment of Adult Patients: A Randomized Controlled Trial

    Viral respiratory infections are common and often require use of health care resources. Patients receive inappropriate bacterial antibiotics, which has many problems including side-effects, development of resistance and costs. A small portion of the infections leads to severe clinical manifestations including hospitalisations and deaths. The significance of influenza virus is well known and it is actively detected in all age groups. However, the benefits of detecting other respiratory viruses have mainly been studied among children but not among adults. The development of multiplex PCR technique has provided a new and sensitive method for diagnosing a large panel of viruses. To convince the economical benefits of the rapid viral diagnostic in adult infectious patient, more evidence is needed. In our randomized study, nasal and pharyngeal samples from the patients evaluated at the emergency clinic of internal medicine in the University Hospital of Oulu because of any respiratory symptom, chest pain or fever, will be collected. The samples will be tested for 16 different respiratory viruses by using Anyplex TMII RV16 Detection. The adult participants will be randomized in two groups. In one group the results of the testing will be reported for the attending physician as soon as possible, and in the other group 7 days after sampling. The effect of this delay to patient care is monitored. Also the results of children and adults are compared as well as results of men and women. The hypothesis is that rapid viral diagnostics shortens the length of admission and diminishes the use of bacterial antibiotics. New information on the viral epidemiology among children and adults is provided and clinical manifestations of specific viral infections in adults are described. The estimated 1500 samples are also tested for 5 different respiratory bacteria by Anyplex TM II RB5 Detection. These results will be examined after completion of the study period. The benefits of rapid bacterial detection are evaluated in respect to the clinical course of the disease and considering the infection control aspects as well.

    NCT02538770
    Conditions
    1. Respiratory Virus Infection
    2. Fever of Unknown Origin
    3. Dyspnea
    4. Chest Pain
    Interventions
    1. Other: Rapid diagnostics using Anyplex TMII RV16 Detection
    2. Other: Delayed diagnostics Anyplex TMII RV16 Detection
    MeSH:Dyspnea Chest Pain Fever of Unknown Origin
    HPO:Chest pain Dyspnea Respiratory distress

    Primary Outcomes

    Description: The number of days in hospital within one month after randomization

    Measure: Duration of hospitalization

    Time: One month

    Description: Number of days on antimicrobials within one month after randomization

    Measure: Antimicrobial consumption

    Time: One month

    Description: Defined daily doses of antimicrobial agents within one month after randomization

    Measure: Antimicrobial consumption

    Time: One month

    Secondary Outcomes

    Measure: Number of radiological examinations

    Time: One month

    Measure: Cost of other examinations in hospital

    Time: One month
    2 Nitric Oxide Gas Inhalation Therapy in Spontaneous Breathing Patients With Mild/Moderate COVID19 Infection: a Randomized Clinical Trial

    The scientific community is in search for novel therapies that can help to face the ongoing epidemics of novel Coronavirus (COVID-19) originated in China in December 2019. At present, there are no proven interventions to prevent progression of the disease. Some preliminary data on SARS pneumonia suggest that inhaled Nitric Oxide (NO) could have beneficial effects on COVID-19 due to the genomic similarities between this two coronaviruses. In this study we will test whether inhaled NO therapy prevents progression in patients with mild to moderate COVID-19 disease.

    NCT04290858
    Conditions
    1. Coronavirus Infections
    2. Pneumonia, Viral
    3. Dyspnea
    Interventions
    1. Drug: Nitric Oxide
    MeSH:Infection Communicable Diseases Coronavirus Infections Severe Acute Respiratory Syndrome Pneumonia, Viral Pneumonia Dyspnea
    HPO:Dyspnea Pneumonia Respiratory distress

    Primary Outcomes

    Description: The primary outcome will be the proportion of patients with mild COVID2019 who deteriorate to a severe form of the disease requiring intubation and mechanical ventilation. Patients with indication to intubation and mechanical ventilation but concomitant DNI (Do Not Intubate) or not intubated for any other reason external to the clinical judgment of the attending physician will be considered as meeting the criteria for the primary endpoint.

    Measure: Reduction in the incidence of intubation and mechanical ventilation

    Time: 28 days

    Secondary Outcomes

    Description: Mortality from all causes

    Measure: Mortality

    Time: 28 days

    Description: Proportion of patients with a negative conversion of RT-PCR from an oropharyngeal or a nasopahryngeal swab

    Measure: Negative conversion of COVID-19 RT-PCR from upper respiratory tract

    Time: 7 days

    Description: Time from initiation of the study to discharge or to normalization of fever (defined as <36.6°C from axillary site, or < 37.2°C from oral site or < 37.8°C from rectal or tympanic site), respiratory rate (< 24 bpm while breathing room air) and alleviation of cough (defined as mild or absent in a patient reported scale of severe >>moderate>>mild>>absent).

    Measure: Time to clinical recovery

    Time: 28 days
    3 Inhaled Aviptadil for the Treatment of Moderate and Severe COVID-19

    Brief Summary: SARS-CoV-2 virus infection is known to cause Lung Injury that begins as dyspnea and exercise intolerance, but may rapidly progress to Critical COVID-19 with Respiratory Failure and the need for noninvasive or mechanical ventilation. Mortality rates as high as 80% have been reported among those who require mechanical ventilation, despite best available intensive care. Patients with moderate and severe COVID-19 by FDA definition who have not developed respiratory failure be treated with nebulized RLF-100 (aviptadil, a synthetic version of Vasoactive Intestinal Polypeptide (VIP)) 100 μg 3x daily plus Standard of Care vs. placebo + Standard of Care using an FDA 501(k) cleared mesh nebulizer. The primary outcome will be progression to in severity of COVID-19 (i.e. moderate progressing to to severe or critical OR severe progressing to critical) over 28 days. Secondary outcomes will include blood oxygenation as measured by pulse oximetry, dyspnea, exercise tolerance, and levels of TNFα IL-6 and other cytokines.

    NCT04360096
    Conditions
    1. SARS-CoV 2
    2. COVID
    3. ARDS
    4. ALI
    5. Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
    6. Dyspnea
    Interventions
    1. Drug: RLF-100 (aviptadil)
    2. Drug: Placebo
    3. Device: Nebulized administration of RLF-100 or Placebo
    MeSH:Respiratory Distress Syndrome, Newborn Respiratory Distress Sy Respiratory Distress Syndrome, Adult Acute Lung Injury Dyspnea Lung Injury
    HPO:Dyspnea Respiratory distress

    Primary Outcomes

    Description: Progression to ARDS is defined as the need for mechanical ventilation

    Measure: Progression to ARDS

    Time: 28 days

    Secondary Outcomes

    Description: Blood PO2 as measured by pulse oximetry

    Measure: Blood oxygenation

    Time: 28 days

    Description: 0 = no shortness of breath at all 0.5 = very, very slight shortness of breath = very mild shortness of breath = mild shortness of breath = moderate shortness of breath or breathing difficulty = somewhat severe shortness of breath = strong or hard breathing 7 = severe shortness of breath or very hard breathing 8 9 = extremely severe shortness of breath 10 = shortness of breath so severe you need to stop the exercise or activity

    Measure: RDP Dsypnea Scale

    Time: 28 days

    Description: Distance walked in six minutes

    Measure: Distance walked in six minutes

    Time: 28 days
    4 Effects of Hydrogen/Oxygen Mixed Gas Inhalation for Patients With Coronavirus Disease 2019 (COVID-19) Who Had Dyspnea: A Multicenter, Open-label Clinical Trial

    This was a randomized, multi-center, open-label clinical trial. Eligible patients were recruited from seven hospitals in China. On the basis of standard-of-care, patients in treatment group inhaled H2-O2 (66% hydrogen; 33% oxygen) at 3 L/min via nasal cannula by using the Hydrogen/Oxygen Generator (model AMS-H-03, Shanghai Asclepius Meditech Co., Ltd., China) until discharge. Patients in control group received standard-of-care (consisting of oxygen therapy) alone until discharge.

    NCT04378712
    Conditions
    1. Covid-19
    2. Hydrogen/Oxygen Mixed Gas
    3. Dyspnea
    Interventions
    1. Device: Hydrogen Oxygen Generator with Nebulizer
    2. Other: Standard-of-care
    MeSH:Dyspnea
    HPO:Dyspnea Respiratory distress

    Primary Outcomes

    Description: The proportion of patients with improved disease severity (by at least one scale) at day 2

    Measure: The proportion of patients with improved disease severity at day 2

    Time: from baseline to day 2

    Description: The proportion of patients with improved disease severity (by at least one scale) at day 3

    Measure: The proportion of patients with improved disease severity at day 3

    Time: from baseline to day 3

    Description: The proportion of patients with improved disease severity (by at least one scale) at the day before hospital discharge

    Measure: The proportion of patients with improved disease severity at the day before hospital discharge

    Time: up to 14 days (from baseline to the day before hospital discharge)

    Secondary Outcomes

    Description: The change from baseline in oxygen saturation at day 2.

    Measure: The change from baseline in oxygen saturation at day 2.

    Time: from baseline to day 2

    Description: The change from baseline in oxygen saturation at day 3.

    Measure: The change from baseline in oxygen saturation at day 3.

    Time: from baseline to day 3

    Description: The change from baseline in oxygen saturation at the day before hospital discharge.

    Measure: The change from baseline in oxygen saturation at the day before hospital discharge

    Time: up to 14 days (from baseline to the day before hospital discharge)

    Description: The change from baseline in dyspnea scale (ranging from 0-4, with higher scores indicating severer outcomes) at day 2.

    Measure: The change from baseline in dyspnea scale at day 2.

    Time: from baseline to day 2

    Description: The change from baseline in dyspnea scale (ranging from 0-4, with higher scores indicating severer outcomes) at day 3.

    Measure: The change from baseline in dyspnea scale at day 3.

    Time: from baseline to day 3

    Description: The change from baseline in dyspnea scale (ranging from 0-4, with higher scores indicating severer outcomes) at the day before hospital discharge.

    Measure: The change from baseline in dyspnea scale at the day before hospital discharge.

    Time: up to 14 days (from baseline to the day before hospital discharge)

    Description: The change from baseline in cough scale (ranging from 0-4, with higher scores indicating severer outcomes) at day 2

    Measure: The change from baseline in cough scale at day 2

    Time: from baseline to day 2

    Description: The change from baseline in cough scale (ranging from 0-4, with higher scores indicating severer outcomes) at day 3

    Measure: The change from baseline in cough scale at day 3

    Time: from baseline to day 3

    Description: The change from baseline in cough scale (ranging from 0-4, with higher scores indicating severer outcomes) at the day before hospital discharge

    Measure: The change from baseline in cough scale at the day before hospital discharge

    Time: up to 14 days (from baseline to the day before hospital discharge)

    Description: The change from baseline in chest pain scale (ranging from 0-4, with higher scores indicating severer outcomes) at day 2.

    Measure: The change from baseline in chest pain scale at day 2.

    Time: from baseline to day 2

    Description: The change from baseline in chest pain scale (ranging from 0-4, with higher scores indicating severer outcomes) at day 3.

    Measure: The change from baseline in chest pain scale at day 3.

    Time: from baseline to day 3

    Description: The change from baseline in chest pain scale (ranging from 0-4, with higher scores indicating severer outcomes) at the day before hospital discharge.

    Measure: The change from baseline in chest pain scale at the day before hospital discharge.

    Time: up to 14 days (from baseline to the day before hospital discharge)

    Description: The change from baseline in chest distress scale (ranging from 0-4, with higher scores indicating severer outcomes) at day 2.

    Measure: The change from baseline in chest distress scale at day 2.

    Time: from baseline to day 2

    Description: The change from baseline in chest distress scale (ranging from 0-4, with higher scores indicating severer outcomes) at day 3.

    Measure: The change from baseline in chest distress scale at day 3.

    Time: from baseline to day 3

    Description: The change from baseline in chest distress scale (ranging from 0-4, with higher scores indicating severer outcomes) at the day before hospital discharge.

    Measure: The change from baseline in chest distress scale at the day before hospital discharge.

    Time: up to 14 days (from baseline to the day before hospital discharge)
    5 An International Observational Study of Outpatients With SARS-CoV-2 Infection

    The general aim of this study is to estimate the rate of disease progression for adults testing positive for SARS-CoV-2. The primary endpoint for this study and the basis for sample size is hospitalization or death during the 28 day follow-up period. In some locations special facilities are being built/utilized for quarantine/public health reasons for those who are SARS-CoV-2 positive. Hospitalization is defined as a stay for at least 18 hours, irrespective of reason, at a hospital or one of these special facilities after study enrollment. Secondary outcomes include participant-reported health status and change in severity of dyspnoea.

    NCT04385251
    Conditions
    1. COVID
    2. COVID19
    3. SARS-CoV 2
    4. Dyspnea
    Interventions
    1. Other: Data Collection
    MeSH:Dyspnea
    HPO:Dyspnea Respiratory distress

    Primary Outcomes

    Description: Outcome reported as the mean number of days from enrollment to hospitalization due to COVID-19.

    Measure: Time to Hospitalization

    Time: 28 days

    Description: Outcome reported as the mean number of days from enrollment to expiration (death) due to COVID-19.

    Measure: Time to Expiration

    Time: 28 days

    Secondary Outcomes

    Description: Outcome reported as the percent of participants who expire due to COVID-19 at 7 days post enrollment.

    Measure: Rate of Death at 7 Days

    Time: 7 days

    Description: Outcome reported as the percent of participants who expire due to COVID-19 at 14 days post enrollment.

    Measure: Rate of Death at 14 Days

    Time: 14 days

    Description: Outcome reported as the percent of participants who expire due to COVID-19 at 28 days post enrollment.

    Measure: Rate of Death at 28 Days

    Time: 28 days

    Description: Outcome reported as the percent of participants who are hospitalized due to COVID-19 at 7 days post enrollment.

    Measure: Rate of Hospitalization at 7 Days

    Time: 7 days

    Description: Outcome reported as the percent of participants who are hospitalized due to COVID-19 at 14 days post enrollment.

    Measure: Rate of Hospitalization at 14 Days

    Time: 14 days

    Description: Outcome reported as the percent of participants who are hospitalized due to COVID-19 at 28 days post enrollment.

    Measure: Rate of Hospitalization at 28 Days

    Time: 28 days

    Description: Outcome reported as the percent of participants who are in excellent or very good health at 7 days post enrollment.

    Measure: Participant Health at 7 Days

    Time: 7 days

    Description: Outcome reported as the percent of participants who are in excellent or very good health at 14 days post enrollment.

    Measure: Participant Health at 14 Days

    Time: 14 days

    Description: Outcome reported as the percent of participants who are in excellent or very good health at 28 days post enrollment.

    Measure: Participant Health at 28 Days

    Time: 28 days

    Description: The Modified Borg Dyspnea scale (MBDS) contains 12 numeric values which designate the severity of dyspnea symptoms (0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10). Higher scores indicate greater dyspnea severity. Outcome is reported as the mean MBDS score at 7 days post enrollment.

    Measure: Modified Borg Dyspnea Scale at 7 Days

    Time: 7 Days

    Description: The Modified Borg Dyspnea scale (MBDS) contains 12 numeric values which designate the severity of dyspnea symptoms (0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10). Higher scores indicate greater dyspnea severity. Outcome is reported as the mean MBDS score at 14 days post enrollment.

    Measure: Modified Borg Dyspnea Scale at 14 Days

    Time: 14 Days

    Description: The Modified Borg Dyspnea scale (MBDS) contains 12 numeric values which designate the severity of dyspnea symptoms (0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10). Higher scores indicate greater dyspnea severity. Outcome is reported as the mean MBDS score at 28 days post enrollment.

    Measure: Modified Borg Dyspnea Scale at 28 Days

    Time: 28 Days
    6 Evaluation of the COVID-19 Infection Response in Patients Admitted to the Emergency Department for Dyspnea

    This research aims to improve our knowledge of the epidemiology of patients consulting in the COvid-19 Possible REspiratory Units (RECOP unit). Indeed, the epidemic linked to COVID-19 affects France and impacts its health system. The reception of all intermediate patients will be on the Emergency Structures (SU). Indeed, the French healthcare system centralizes unscheduled urgent care on the ER. The aspecific respiratory symptomatology in "intermediate" patients indicates them all the more at an admission to SU or the diagnostic approach to respiratory difficulty may be carried out. A central issue of this diagnostic strategy will be to be rapid, since the diagnosis will have to be made in the context of significant flows, with a need to quickly refer patients to the most suitable downstream service, while limiting the risk contamination of caregivers and vulnerable patients if a COVID-19 + patient is admitted to an unsuitable service. However, virological tests do not currently allow rapid results for COVID-19. Research project of investigatory aims to develop a predictive model of the risk of being COVID-19 positive for patients admitted to the emergency room for acute dyspnea.

    NCT04422587
    Conditions
    1. Emergencies
    Interventions
    1. Other: RECOP unit patient
    MeSH:Dyspnea Emergencies
    HPO:Dyspnea Respiratory distress

    Primary Outcomes

    Description: demographic variables, usual history and treatments, episode characteristics (symptomatology, evolution, treatment taken) and data from the initial clinical examination will be collected by doctor

    Measure: Develop a predictive model of the risk of being COVID-19 for patients admitted to the emergency room for dyspnea

    Time: inclusion day

    Secondary Outcomes

    Description: The COVID-19 virological condition will be taken with PCR tests on naso-pharyngeal samples or on sputum for patients taking

    Measure: Describe the characteristics of patients admitted to reCOP units according to their virological status

    Time: 30 days

    Description: Virological status will be collected by a phone call at the patient

    Measure: Virological status

    Time: 30 days

    Description: Mortality status will be collected by a phone call at the patient

    Measure: Mortality status

    Time: 30 days
    7 Knowledge, Attitude and Practice About COVID-19 and Awareness of Infection Control to Prevent COVID-19 Transmission in Clinics and Perception About Online Learning During Lock Down Period: A Cross-sectional Study

    Coronavirus disease 2019 (abbreviated "COVID- 19") is a pandemic respiratory disease that is caused by a novel coronavirus and was first detected in December 2019 in Wuhan, China. The disease is highly infectious, and its main clinical symptoms include fever, dry cough, fatigue, myalgia, and dyspnoea.1 In China, 18.5% of the patients with COVID-19 developed to the severe stage, which is characterized by acute respiratory distress syndrome, septic shock, difficult-to-tackle metabolic acidosis, and bleeding and coagulation dysfunction. After China, COVID-19 spread across the world and many governments implemented unprecedented measures like suspension of public transportation, the closing of public spaces, close management of communities, and isolation and care for infected people and suspected cases. The Malaysian government had enforced Movement Control Order (MCO) from 18th March to 4th May 2020 and henceforth Conditional Movement Control Order (CMCO) until 9th June 2020. The battle against COVID-19 is still continuing in Malaysia and all over the world. Due to the CMO and CMCO in the country, public and private universities have activated the e-learning mode for classes and as the government ordered, universities are closed and no face-to-face activities allowed. This has forced students of all disciplines including dentistry to stay at home which are wide-spread across Malaysia and shift to e- learning mode. To guarantee the final success for fight against COVID-19, regardless of their education status, students' adherence to these control measures are essential, which is largely affected by their knowledge, attitudes, and practices (KAP) towards COVID-19 in accordance with KAP theory. Once the restrictions are eased students have to come back and resume their clinical work in the campus. Hence, in this study we assessed the Knowledge, Attitude, and Practice (KAP) towards COVID-19 and the students preference for online learning.

    NCT04449081
    Conditions
    1. Acute Respiratory Distress Syndrome
    2. Corona Virus Infection
    3. Acute Lung Injury
    4. Fever
    5. Myalgia
    6. Cough
    7. Dyspnea
    8. Septic Shock
    9. Bleeding
    Interventions
    1. Behavioral: Knowledge, Attitude, Practice, Awareness, Preference
    MeSH:Infection Coronavirus Infections Severe Acute Respiratory Syndrome Myalgia Respiratory Distress Syndrome, Newborn Respiratory Distress Syndrome, Adult Acute Lung Injury Dyspnea Lung Injury
    HPO:Dyspnea Myalgia Respiratory distress

    Primary Outcomes

    Description: KAP towards COVID-19 was assessed using validated questionnnaire

    Measure: Knowledge, Attitude, Practice of dental students towards COVID-19

    Time: 4 months

    Secondary Outcomes

    Description: Awareness level about Infection control to prevent COVID-19 transmission in clinics was assesed using a standardized questionnaire

    Measure: Awareness level about Infection control to prevent COVID-19 transmission in clinics

    Time: 4 months

    Description: Preference towards online learning. was assessed using a standard questionnaire

    Measure: Preference towards online learning.

    Time: 4 months
    8 Follow-up of Respiratory Sequelae of Patients Hospitalized With SARS-CoV-2: a Prospective Multicenter Observational Study

    The objective of this multicenter observational study is to describe respiratory sequelae of COVID-19 patients hospitalized for severe pneumonia requiring oxygen supply.

    NCT04505631
    Conditions
    1. Covid19
    2. Dyspnea
    MeSH:Dyspnea
    HPO:Dyspnea Respiratory distress

    Primary Outcomes

    Description: The presence of respiratory sequelae will be assessed by low dose thoracic tomodensitometry

    Measure: Presence of respiratory sequelae

    Time: 6 months after hospital discharge

    Secondary Outcomes

    Measure: Presence of respiratory sequelae on low dose thoracic tomodensitometry

    Time: 3 months after hospital discharge

    Description: Respiratory functional exploration

    Measure: Forced vital capacity (FVC, %)

    Time: 6 months after hospital discharge

    Description: Respiratory functional exploration

    Measure: Forced vital capacity (FVC, %)

    Time: 3 months after hospital discharge

    Description: Respiratory functional exploration

    Measure: Forced expiratory volume in 1 second (FEV1, %)

    Time: 6 months after hospital discharge

    Description: Respiratory functional exploration

    Measure: Forced expiratory volume in 1 second (FEV1, %)

    Time: 3 months after hospital discharge

    Description: Respiratory functional exploration

    Measure: Tiffeneau-Pinelli index (FEV1/FVC, %)

    Time: 6 months after hospital discharge

    Description: Respiratory functional exploration

    Measure: Tiffeneau-Pinelli index (FEV1/FVC, %)

    Time: 3 months after hospital discharge

    Description: Respiratory functional exploration

    Measure: Total lung capacity (TLC, %)

    Time: 6 months after hospital discharge

    Description: Respiratory functional exploration

    Measure: Total lung capacity (TLC, %)

    Time: 3 months after hospital discharge

    Description: Respiratory functional exploration

    Measure: Residual volume (RV, %)

    Time: 6 months after hospital discharge

    Description: Respiratory functional exploration

    Measure: Residual volume (RV, %)

    Time: 3 months after hospital discharge

    Description: Respiratory functional exploration

    Measure: RV/TLC ratio (%)

    Time: 6 months after hospital discharge

    Description: Respiratory functional exploration

    Measure: RV/TLC ratio (%)

    Time: 3 months after hospital discharge

    Description: Respiratory functional exploration

    Measure: Maximal inspiratory pressure (MIP, %)

    Time: 6 months after hospital discharge

    Description: Respiratory functional exploration

    Measure: Maximal inspiratory pressure (MIP, %)

    Time: 3 months after hospital discharge

    Description: Respiratory functional exploration

    Measure: Maximal expiratory pressure (MEP, %)

    Time: 6 months after hospital discharge

    Description: Respiratory functional exploration

    Measure: Maximal expiratory pressure (MEP, %)

    Time: 3 months after hospital discharge

    Description: Respiratory functional exploration

    Measure: Diffusion capacity of the lungs for carbon monoxide (DLCO, %)

    Time: 6 months after hospital discharge

    Description: Respiratory functional exploration

    Measure: Diffusion capacity of the lungs for carbon monoxide (DLCO, %)

    Time: 3 months after hospital discharge

    Description: Arterial gasometry will be performed under ambient air and under oxygen

    Measure: pH

    Time: 6 months after hospital discharge

    Description: Arterial gasometry will be performed under ambient air and under oxygen

    Measure: pH

    Time: 3 months after hospital discharge

    Description: Arterial gasometry will be performed under ambient air and under oxygen

    Measure: Arterial oxygen partial pressure (PaO2, mmHg)

    Time: 6 months after hospital discharge

    Description: Arterial gasometry will be performed under ambient air and under oxygen

    Measure: Arterial oxygen partial pressure (PaO2, mmHg)

    Time: 3 months after hospital discharge

    Description: Arterial gasometry will be performed under ambient air and under oxygen

    Measure: Arterial carbon dioxide partial pressure (PaCO2, mmHg)

    Time: 6 months after hospital discharge

    Description: Arterial gasometry will be performed under ambient air and under oxygen

    Measure: Arterial carbon dioxide partial pressure (PaCO2, mmHg)

    Time: 3 months after hospital discharge

    Description: Arterial gasometry will be performed under ambient air and under oxygen

    Measure: Bicarbonate concentration (mmol/L)

    Time: 6 months after hospital discharge

    Description: Arterial gasometry will be performed under ambient air and under oxygen

    Measure: Bicarbonate concentration (mmol/L)

    Time: 3 months after hospital discharge

    Description: Arterial gasometry will be performed under ambient air and under oxygen

    Measure: Arterial oxygen saturation (SaO2, %)

    Time: 6 months after hospital discharge

    Description: Arterial gasometry will be performed under ambient air and under oxygen

    Measure: Arterial oxygen saturation (SaO2, %)

    Time: 3 months after hospital discharge

    Description: Six-minute walk test will be performed under ambient air and under oxygen

    Measure: Six-minute walk test

    Time: 6 months after hospital discharge

    Description: Six-minute walk test will be performed under ambient air and under oxygen

    Measure: Six-minute walk test

    Time: 3 months after hospital discharge
    9 Retrospective Study of the Measurement of the Efficacy of MORPHINE in the Early Management of Dyspnea in COVID-19 Positive Patients With Moderate to Severe Impairment Without Objective of Resuscitation Management (Level of Care 3 and 4) at the Hospices Civils of Lyon

    Morphine is used in the treatment of dyspnea and polypnea with a proven benefit on the improvement of these symptoms, both etiologically and symptomatically. This medication is used in particular in palliative care for this type of symptom. The Sars CoV2 viral pneumonia table can lead to respiratory distress. In patients with moderate to severe impairment without goal of resuscitation (level of care 3 and 4), the introduction of morphine may sometimes be necessary to relieve respiratory symptoms. These also lead to major exhaustion which can worsen the clinical picture. However, the prescription of morphine is not systematic in front of a respiratory distress table. The investigators hypothesized that early treatment with morphine lead to a better management of dyspnea, quality of live and survival in COVID-19 positive participants patients when there is not resuscitation objective management (level of care 3 and 4). The objective is to measure the efficacy of morphine in the early management of dyspnea, quality of life and survival in COVID-19 positive participants patients treated in the Hospices Civils of Lyon during COVID-19 pandemic.

    NCT04522037
    Conditions
    1. Patients Hospitalized in the Hospices Civils of Lyon
    2. COVID-19 Disease
    3. Moderate to Severe Dyspnea
    4. Without Resuscitation Objective Management
    Interventions
    1. Other: No intervention / Compare the difference in respiratory rate between H0 and H12 of the initiation of morphine between the control and interventional groups
    MeSH:Dyspnea
    HPO:Dyspnea Respiratory distress

    Primary Outcomes

    Description: The respiratory rate is analyzed at Hour 0 and Hour 12 by a scope.

    Measure: Title : Reduction of respiratory rate between Hour 0 and Hour 12 at initiation of morphine treatment

    Time: Hour 0 and Hour 12 after initiation of morphinic treatment
    10 Effectiveness of an Exercise Re-training Program on Dyspnea in Patients After Acute Respiratory Distress Syndrome Secondary to Severe COVID-19 Pneumonia in Post-ICU

    Dyspnea is defined by a subjective sensation of respiratory discomfort, the intensity of which varies according to the terrain, the anamnesis and the cause. Resuscitation is associated with many causes of dyspnea, including initial distress, mechanical ventilation, or after-effects following the pathology and its management. Respiratory distress is the most severe form of impaired lung function. It is the first cause of hospitalization in intensive care. This distress, indicative of the failure of the respiratory system, is always severe and potentially fatal. It therefore constitutes an absolute therapeutic emergency. Dyspnea is often the revealing symptom of the condition and the urgency surrounding its management is an additional factor of concern for the patient. As a result, dyspnea is a pejorative element associated with severity or even death.

    NCT04569266
    Conditions
    1. Dyspnea
    Interventions
    1. Other: specific exercise rehabilitation treatment
    MeSH:Pneumonia Respiratory Distress Syndrome, Newborn Respiratory Distress Syndrome, Adult Acute Lung Injury Dyspnea
    HPO:Dyspnea Pneumonia Respiratory distress

    Primary Outcomes

    Description: Multidimensional Dyspnea Profile (MDP) scale assessment of dyspnea

    Measure: Evaluate the effect of exercise rehabilitation on post-ICU dyspnea

    Time: Day 1

    Description: Multidimensional Dyspnea Profile (MDP) scale assessment of dyspnea

    Measure: Evaluate the effect of exercise rehabilitation on post-ICU dyspnea

    Time: 3 Months

    Secondary Outcomes

    Description: Assessment of dyspnea on the Modified Medical Research Council (mMRC) scale

    Measure: Evaluate the effect of exercise rehabilitation on functional dyspnea

    Time: Day 1

    Description: Assessment of dyspnea on the Modified Medical Research Council (mMRC) scale

    Measure: Evaluate the effect of exercise rehabilitation on functional dyspnea

    Time: 3 Months

    Description: Short-Form Quality of Life Assessment (SF-12)

    Measure: Evaluate the effect of stress rehabilitation on quality of life

    Time: Day 1

    Description: Short-Form Quality of Life Assessment (SF-12)

    Measure: Evaluate the effect of stress rehabilitation on quality of life

    Time: 3 Months
    11 A Self - Guided, Internet - Based Intervention for Patients With Chronic Breathlessness (SELF-BREATHE): Feasibility Randomised Controlled Trial

    A feasibility RCT comprising two groups: 1. Intervention (SELF-BREATHE in addition to standard NHS care) 2. Control group (standard / currently available NHS care)

    NCT04574050
    Conditions
    1. Cancer
    2. COPD
    3. Asthma
    4. Bronchiectasis Adult
    5. Interstitial Lung Disease
    6. Cystic Fibrosis
    7. Chronic Heart Failure
    8. Sickle Cell Disease
    9. Renal Failure
    10. Liver Failure
    11. Post COVID-19
    12. Dyspnea
    Interventions
    1. Other: SELF-BREATHE
    MeSH:Cystic Fibrosis Liver Failure Lung Diseases Dyspnea Bronchiectasis Lung Diseases, Interstitial Anemia, Sickle Cell
    HPO:Abnormal lung morphology Abnormal pulmonary Interstitial morphology Bronchiectasis Dyspnea Hepatic failure Interstitial pneumonitis Respiratory distress

    Primary Outcomes

    Description: The number of patients recruited into this study over a 12-month period

    Measure: Feasibility: the number of patients recruited into this study over a 12-month period

    Time: 12 months

    HPO Nodes


    Reports

    Data processed on December 13, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,818 reports on interventions/drugs

    MeSH

    706 reports on MeSH terms

    HPO

    306 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook